BLRD Research Career Scientist Award Application

这项提案旨在延长苏布赫拉博士举办的研究职业科学家奖 莫哈帕特拉，自2018年以来在佛罗里达州坦帕市的詹姆斯·A·黑利VA医院工作。她也是一名终身教职的- 退伍军人事务部附属学术中心南佛罗里达大学的全职教授(兼职)。她 是多个国际/国家奖项和认可的获得者，包括作为 美国国家发明家学会和美国医学与生物研究所研究员 工程学。年，莫哈帕特拉博士一直在退伍军人医院(医学)担任研究调查员。 2007年，并一直得到关注癌症、创伤的功绩回顾奖的资助 脑损伤(TBI)，以及自2016年以来的COVID。她一直在研究基础分子和 各种急性/慢性疾病炎症的翻译机制包括 新冠肺炎、癌症和脑外伤，所有这些都困扰着退伍军人管理局人口，并在很大程度上导致 退伍军人的整体健康状况。她的研究计划的主要前提是 了解疾病发病机制，开发新的致病机制 诊断/预后和治疗方法。当前和正在进行的研究 由RCS奖支持的活动主要集中在三个方面。第一个项目的中心是 新型预防和/或病毒中和纳米粒的表征 新冠肺炎患者的治疗。在这项提议中，这些粒子将被研究它们的潜力 并在相关的人类细胞和小鼠模型中进行了验证。她正在与其他退伍军人管理局合作 研究人员正在开发一个额外的项目，以开发基于siRNA的新型预防和 针对急性SARS后病毒复制和细胞因子风暴的治疗方法- 冠状病毒2型感染。第二个研究项目集中在对一部小说的调查 包括鼻腔给药的中度脑外伤小鼠模型的综合治疗方法 针对新近发现的靶点CCL20的树状大分子纳米配方siRNA治疗 减少炎症，并通过治疗促进神经再生的平行治疗 间充质干细胞。在第三个研究项目中，莫哈帕特拉博士的实验室旨在研究 并使用间充质干细胞测试一种新的靶向溶瘤病毒细胞疗法治疗肺癌 被呼吸道合胞病毒感染的细胞，这对免疫功能无害 个人。该项目使用3D多细胞肿瘤样体和活体组织来源的体外培养物， 这是她的实验室首创的。此外，该项目使用体内肺癌小鼠模型来 评价溶瘤病毒细胞治疗的安全性和有效性。到目前为止，这个项目已经吸引了 行业合作，这可能导致临床试验。总体而言，这些高度创新的 这些方法结合在一起有望带来高影响力的临床诊断和治疗。 为退伍军人和其他有需要的美国人治疗各种疾病。退伍军人一直是 按比例受到大流行的影响，并越来越多地受到肺部发病率的影响 癌症和脑外伤与普通人群相比。拥有约100种出版物，20项专利，以及 指数为36，I指数为85，苏布拉·莫哈帕特拉博士在全国范围内得到认可 国际上表彰她在癌症、神经退行性疾病等领域的研究贡献 和病毒感染。她得到了包括奖项在内的大量校外研究支持 来自美国国立卫生研究院、ONR、退伍军人事务部和佛罗里达州卫生部。它是 预计这些有效疗法的开发将极大地提高 退伍军人医疗保健。

This proposal seeks to renew Research Career Scientist Award held by Dr. Subhra Mohapatra, at the James A. Haley VA Hospital in Tampa, Florida since 2018. She is also a tenured- full professor (part-time) at the VA-affiliated academic center- the University of South Florida. She is the recipient of several international/national awards and recognitions including as a Fellow of the National Academy of Inventors and a Fellow of the American Institute for Medical and Biological Engineering. Dr. Mohapatra has been a research investigator at the VA Hospital (Medicine) since 2007 and has been continuously funded with the Merit Review Award focused on cancer, traumatic brain injury (TBI), and COVID since 2016. She has been studying the basic molecular and translational mechanisms underlying the inflammation in diverse acute/chronic diseases including COVID-19, cancers, and TBI, all of which afflict VA population and contribute significantly to the overall health of the Veterans. The main premise of her research program has been to understand the mechanisms involved in the disease pathogenesis toward developing novel diagnostic/prognostic and therapeutic approaches to treat them. Current and ongoing research activities to be supported by this RCS Award focus on three areas. The first program centers on the characterization of novel virus-neutralizing nanoparticles that may serve as prophylactic and/or treatment for COVID-19 patients. In this proposal, these particles will be investigated for their potential and validated in relevant human cellular and mouse models. She is collaborating with other VA investigators in developing an additional project to develop novel siRNA-based prophylactic and therapeutic approaches targeting viral replication and cytokine storm that follows acute SARS- CoV-2 infection. The second research program focuses on the investigation of a novel combinatorial therapeutic approach in a mouse model of moderate TBI that includes an intranasal dendrimer-based nano-formulated siRNA treatment against a recently discovered target, CCL20 to reduce inflammation, and a parallel treatment to promote neuroregeneration by therapy with mesenchymal stem cells. In the third research program Dr. Mohapatra’s lab aims to investigate and test a novel targeted oncolytic viro-cell therapy for lung cancer using the mesenchymal stem cells infected by a respiratory syncytial virus infection, which is harmless for immunocompetent individuals. This project uses a 3D multicell tumoroid in vitro and biopsy-derived cultures ex vivo, which her lab has pioneered. Further, this project uses in vivo mouse models of lung cancer to evaluate the safety and efficacy of oncolytic viro-cell therapy. The project to date has attracted industry collaboration, which might lead to clinical trials. Overall, these highly innovative approaches taken together are expected to lead to high-impact clinical diagnostics and therapies for diverse diseases of Veterans and other Americans in need. Veterans have been proportionately affected by the pandemic and are increasingly affected by the incidence of lung cancers and TBI compared to the general population. With ~100 publications, 20 patents, an h- index of 36 and an i-index of 85, Dr. Subhra Mohapatra is recognized nationally and internationally for her contributions to the fields of research on cancer, neurodegenerative disease, and viral infections. She has received substantial extramural research support including awards from the NIH, ONR, Department of Veterans Affairs, and Florida Department of Health. It is anticipated that the development of these effective therapeutics will greatly improve the quality of Veteran’s healthcare.